Skip to main content

Home/ Healthcare 2.0/ Group items tagged MyelofibrosisTreatmentMarketForecast

Rss Feed Group items tagged

sachin_cmi

Myelofibrosis Treatment Market Continues To Grow Owing To the Demand from Healthcare Se... - 0 views

  •  
    Myelofibrosis Treatment includes medications and surgery. There are drugs and medicines which are used to cure myelofibrosis. Myelofibrosis is a muscle disease and various types of myelofibrosis treatment are available in the market to cure this condition. The muscle disease is caused due to myelodysplasia, a genetically determined trait that prevents the muscle from growing properly. Myelofibrosis is also known as spider veins, lying in regions close to the skin, like the armpits, groin, elbows, and knees. Myelofibrosis is the most common type of connective tissue disease. These medicines are generally used to control and stop the progress of the disease, after which, they suppress the activity of the immune system. Various types of steroids are used as medicines for myelofibrosis, to control the activity of the immune system and thereby stop the disease in its tracks. One of the most common drugs for myelofibrosis treatment is prednisone, which is generally used along with steroids. However, to treat spider veins and not myelofibrosis, a compound called Finasteride is used. The most important part of myelofibrosis treatment is a regular check-up, as early as 18 months of the disease a doctor can monitor the progress of the disease. Myelofibrosis treatment also includes physical therapy and other treatments to improve the symptoms of myelofibrosis. The main driving factor influencing the growth of the myelofibrosis treatment market is the increasing prevalence of myelofibrosis in emerging economies. For instance, according to Gleneagles Global Hospitals, the yearly incidence rate of myelofibrosis in India is 0.3 to 1.5 cases per 100,000 individuals. Most of the times these cases goes unnoticed since it is sometimes asymptomatic or less severe. Moreover, the market is estimated to grow owing to a large number of R&D investments, a large cluster of patients suffering from myelofibrosis, and better reimbursement policies. Read more @ https://coherentmarketinsights-bl
1 - 1 of 1
Showing 20 items per page